ATE549350T1 - Neuropeptid-2-rezeptor-agonisten - Google Patents
Neuropeptid-2-rezeptor-agonistenInfo
- Publication number
- ATE549350T1 ATE549350T1 AT06830133T AT06830133T ATE549350T1 AT E549350 T1 ATE549350 T1 AT E549350T1 AT 06830133 T AT06830133 T AT 06830133T AT 06830133 T AT06830133 T AT 06830133T AT E549350 T1 ATE549350 T1 AT E549350T1
- Authority
- AT
- Austria
- Prior art keywords
- neuropeptide
- receptor agonists
- agonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74807105P | 2005-12-07 | 2005-12-07 | |
US85524906P | 2006-10-30 | 2006-10-30 | |
PCT/EP2006/068924 WO2007065808A2 (en) | 2005-12-07 | 2006-11-27 | Neuropeptide-2 receptor-agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE549350T1 true ATE549350T1 (de) | 2012-03-15 |
Family
ID=37964711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06830133T ATE549350T1 (de) | 2005-12-07 | 2006-11-27 | Neuropeptid-2-rezeptor-agonisten |
Country Status (18)
Country | Link |
---|---|
US (2) | US7642244B2 (de) |
EP (1) | EP1962959B1 (de) |
JP (1) | JP5000663B2 (de) |
KR (1) | KR101059602B1 (de) |
AR (1) | AR057222A1 (de) |
AT (1) | ATE549350T1 (de) |
AU (1) | AU2006324076A1 (de) |
BR (1) | BRPI0619573A2 (de) |
CA (1) | CA2630649A1 (de) |
EC (1) | ECSP088511A (de) |
ES (1) | ES2381497T3 (de) |
IL (1) | IL191636A (de) |
MA (1) | MA30142B1 (de) |
NO (1) | NO20082445L (de) |
NZ (1) | NZ568772A (de) |
RU (2) | RU2430108C2 (de) |
TW (1) | TWI321474B (de) |
WO (1) | WO2007065808A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010069242A (ko) * | 2000-09-05 | 2001-07-25 | 양우용 | 저주파 물리치료 겸용 혈압 강하기 |
ES2381497T3 (es) * | 2005-12-07 | 2012-05-28 | F. Hoffmann-La Roche Ag | Agonistas del receptor del neuropéptido-2 |
US8299023B2 (en) * | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
KR20110097807A (ko) * | 2008-11-05 | 2011-08-31 | 에프. 호프만-라 로슈 아게 | 뉴로펩티드-2-수용체(y-2r) 작용제 및 이의 용도 |
EP2450374B9 (de) | 2009-07-02 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Peptid und seine verwendung |
WO2011033068A1 (en) * | 2009-09-18 | 2011-03-24 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
CA2776302A1 (en) * | 2009-10-13 | 2011-04-21 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor (y-2r) agonists |
RS56998B1 (sr) | 2010-12-16 | 2018-05-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
RU2013135175A (ru) * | 2011-01-03 | 2015-02-10 | Ф. Хоффманн-Ля Рош Аг | Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом |
RU2641198C3 (ru) | 2012-03-22 | 2021-12-10 | Ново Нордиск А/С | Композиции glp-1 пептидов и их получение |
BR112014030843A2 (pt) | 2012-07-04 | 2019-10-15 | Hoffmann La Roche | anticorpo anti-teofilina, formulação farmacêutica e uso do anticorpo |
EP2870180B1 (de) | 2012-07-04 | 2024-08-28 | F. Hoffmann-La Roche AG | Anti-biotin-antikörper und verwendungsverfahren |
SI2869848T1 (sl) | 2012-07-04 | 2017-01-31 | F. Hoffmann-La Roche Ag | Kovalentno vezani konjugati antigen-protitelo |
US9085637B2 (en) | 2013-11-15 | 2015-07-21 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
US10583172B2 (en) | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
CN105873615B (zh) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | 共价连接的helicar-抗helicar抗体缀合物及其用途 |
RU2682754C2 (ru) | 2014-01-03 | 2019-03-21 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью |
PL3089996T3 (pl) | 2014-01-03 | 2021-12-13 | F. Hoffmann-La Roche Ag | Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg |
MA41898A (fr) * | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
WO2016198682A1 (en) | 2015-06-12 | 2016-12-15 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
IL275778B2 (en) | 2018-02-02 | 2023-12-01 | Novo Nordisk As | Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt |
WO2021094259A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | Npy2 receptor agonists |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
AUPO029096A0 (en) | 1996-06-05 | 1996-07-04 | Crc For Biopharmaceutical Research Pty Ltd | Npy y2 agonists |
US6013633A (en) * | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
EP2277527A3 (de) * | 2003-01-17 | 2011-08-31 | Ipsen Pharma | Peptid YY Analoge |
ES2512499T3 (es) | 2003-04-08 | 2014-10-24 | Yeda Research And Development Co., Ltd. | Fármacos pegilados reversibles |
CA2545408A1 (en) | 2003-11-25 | 2005-06-16 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
EP1718671A2 (de) | 2004-02-23 | 2006-11-08 | Rheoscience A/S | Peptid-yy-analoga |
US7410949B2 (en) * | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
WO2006091505A2 (en) | 2005-02-24 | 2006-08-31 | Bayer Pharmaceuticals Corporation | Neuropeptide y receptor agonists |
ES2381497T3 (es) * | 2005-12-07 | 2012-05-28 | F. Hoffmann-La Roche Ag | Agonistas del receptor del neuropéptido-2 |
WO2007085887A1 (en) | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Pyy agonists and uses thereof |
-
2006
- 2006-11-27 ES ES06830133T patent/ES2381497T3/es active Active
- 2006-11-27 AT AT06830133T patent/ATE549350T1/de active
- 2006-11-27 RU RU2008127265/04A patent/RU2430108C2/ru not_active IP Right Cessation
- 2006-11-27 JP JP2008543768A patent/JP5000663B2/ja not_active Expired - Fee Related
- 2006-11-27 CA CA002630649A patent/CA2630649A1/en not_active Abandoned
- 2006-11-27 KR KR1020087016291A patent/KR101059602B1/ko not_active IP Right Cessation
- 2006-11-27 NZ NZ568772A patent/NZ568772A/en not_active IP Right Cessation
- 2006-11-27 WO PCT/EP2006/068924 patent/WO2007065808A2/en active Application Filing
- 2006-11-27 BR BRPI0619573-3A patent/BRPI0619573A2/pt not_active IP Right Cessation
- 2006-11-27 EP EP06830133A patent/EP1962959B1/de active Active
- 2006-11-27 AU AU2006324076A patent/AU2006324076A1/en not_active Abandoned
- 2006-12-01 US US11/607,230 patent/US7642244B2/en not_active Expired - Fee Related
- 2006-12-04 TW TW095145032A patent/TWI321474B/zh not_active IP Right Cessation
- 2006-12-05 AR ARP060105368A patent/AR057222A1/es active IP Right Grant
-
2008
- 2008-05-22 IL IL191636A patent/IL191636A/en not_active IP Right Cessation
- 2008-05-28 NO NO20082445A patent/NO20082445L/no not_active Application Discontinuation
- 2008-06-06 EC EC2008008511A patent/ECSP088511A/es unknown
- 2008-07-01 MA MA31085A patent/MA30142B1/fr unknown
-
2009
- 2009-08-06 US US12/536,688 patent/US8268784B2/en not_active Expired - Fee Related
-
2011
- 2011-02-15 RU RU2011105310/04A patent/RU2011105310A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20080082672A (ko) | 2008-09-11 |
NO20082445L (no) | 2008-09-03 |
KR101059602B1 (ko) | 2011-08-25 |
JP5000663B2 (ja) | 2012-08-15 |
AR057222A1 (es) | 2007-11-21 |
RU2430108C2 (ru) | 2011-09-27 |
MA30142B1 (fr) | 2009-01-02 |
NZ568772A (en) | 2010-05-28 |
US7642244B2 (en) | 2010-01-05 |
BRPI0619573A2 (pt) | 2011-10-04 |
AU2006324076A1 (en) | 2007-06-14 |
EP1962959B1 (de) | 2012-03-14 |
WO2007065808A2 (en) | 2007-06-14 |
CA2630649A1 (en) | 2007-06-14 |
ECSP088511A (es) | 2008-07-30 |
TW200806311A (en) | 2008-02-01 |
EP1962959A2 (de) | 2008-09-03 |
US8268784B2 (en) | 2012-09-18 |
RU2008127265A (ru) | 2010-01-20 |
TWI321474B (en) | 2010-03-11 |
IL191636A (en) | 2012-10-31 |
WO2007065808A3 (en) | 2007-08-02 |
RU2011105310A (ru) | 2012-08-20 |
JP2009518349A (ja) | 2009-05-07 |
US20100137223A1 (en) | 2010-06-03 |
US20070135351A1 (en) | 2007-06-14 |
IL191636A0 (en) | 2008-12-29 |
ES2381497T3 (es) | 2012-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE549350T1 (de) | Neuropeptid-2-rezeptor-agonisten | |
DE602006007563D1 (de) | Agonisten | |
DK1973886T3 (da) | Prokineticin-1-receptor-antagonister | |
DK3354273T3 (da) | Melanocortinreceptorligander | |
DK1928882T3 (da) | (s)-n-methylnaltrexon | |
ATE408603T1 (de) | Pyrazolylcarboxanilide | |
CR9974A (es) | Gavión | |
DE602006020447D1 (de) | Niacin-rezeptoragonisten, zusammensetzungen mit de | |
DK1989196T3 (da) | Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister | |
BRPI0807911A2 (pt) | Agonistas de alfa2c adrenorreceptor | |
ATE549324T1 (de) | Tetrahydrobenzoxazine | |
DK1870409T3 (da) | Benzimidazolforbindelser | |
ES1064680Y (es) | Estructura portante de receptor | |
DE112006002964A5 (de) | Zweirichtungsreflektanzverteilungsmessgerät | |
DE502005005839D1 (de) | Feldgeerät | |
DE502006001397D1 (de) | Lagerbuchse | |
ATE485368T1 (de) | Hiv - impfung | |
DE502006001004D1 (de) | Hydrolager | |
DE102005052834B8 (de) | Punktschweißklebverbindung | |
DK1904404T3 (da) | Mærkede uorganiske additiver | |
DE602006021285D1 (de) | Mikrotomklinge | |
AT501523A3 (de) | Estrich | |
DE502006002822D1 (de) | Ges | |
DE102006033170A8 (de) | Einfassnähmaschine | |
DE502006000445D1 (de) | Mulchmähdeck |